Ensysce Biosciences Inc (ENSC)

$0.37 -0.03 (-6.62%)
Market Cap 1.44M
Revenue (ttm) 5.21M
Net Income (ttm) -7.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -153.36%
Debt to Equity Ratio 0.00
Volume 560,926
Avg Vol 1,215,150
Day's Range N/A - N/A
Shares Out 3.63M
Stochastic %K 22%
Beta 1.17
Analysts Strong Buy
Price Target $16.45

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 263 4196
Address:
7946 Ivanhoe Avenue, Suite 201, La Jolla, United States
Bhaddar1
Bhaddar1 Feb. 23 at 9:58 PM
$ENSC we looking for next jumb for .50 range and then we off to moon 🌙
0 · Reply
Djdanny
Djdanny Feb. 23 at 9:28 PM
$ENSC Super hammered stock .Potential gg reward.
0 · Reply
Ctr_
Ctr_ Feb. 23 at 9:15 PM
$ENSC has been going sideways .35 & .38 since feb 18. waiting for structure
0 · Reply
Big_Zack22
Big_Zack22 Feb. 23 at 7:44 PM
$ENSC Hold on my budy
0 · Reply
Big_Zack22
Big_Zack22 Feb. 23 at 7:27 PM
$ENSC loading zone
0 · Reply
PTI127
PTI127 Feb. 23 at 2:19 PM
$ENSC gifted here buy and hold 😘
1 · Reply
ttesty
ttesty Feb. 23 at 2:07 PM
$ENSC on the road to $0.
1 · Reply
Bhaddar1
Bhaddar1 Feb. 23 at 12:33 PM
$ENSC loud up 🆙
0 · Reply
Magnatar
Magnatar Feb. 23 at 3:27 AM
$ENSC “Dark Pool Ale” - Bring It $$
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 12:39 AM
$ENSC RSI: 26.64, MACD: -0.1566 Vol: 0.18, MA20: 0.58, MA50: 0.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on ENSC
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

Feb 23, 2026, 8:00 AM EST - 9 hours ago

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Jan 28, 2026, 8:00 AM EST - 26 days ago

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Jan 21, 2026, 8:00 AM EST - 4 weeks ago

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Jan 8, 2026, 8:00 AM EST - 6 weeks ago

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript

Jan 7, 2026, 1:38 PM EST - 6 weeks ago

Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript

Ensysce Biosciences Issues Annual Shareholder Letter

Jan 5, 2026, 8:00 AM EST - 7 weeks ago

Ensysce Biosciences Issues Annual Shareholder Letter

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Dec 12, 2025, 8:00 AM EST - 2 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Dec 9, 2025, 8:00 AM EST - 2 months ago

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Dec 2, 2025, 8:00 AM EST - 2 months ago

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Nov 20, 2025, 8:00 AM EST - 3 months ago

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 17, 2025, 8:05 AM EST - 3 months ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:15 PM EST - 3 months ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Oct 10, 2025, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 19, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Aug 13, 2025, 4:15 PM EDT - 6 months ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 31, 2025, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jul 16, 2025, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 24, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 11, 2025, 8:00 AM EDT - 9 months ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Jun 4, 2025, 8:00 AM EDT - 9 months ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 13, 2025, 4:15 PM EDT - 10 months ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

May 12, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 24, 2025, 4:15 PM EDT - 10 months ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Apr 23, 2025, 5:11 PM EDT - 10 months ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 4:41 PM EDT - 10 months ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 23, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Apr 15, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Mar 3, 2025, 9:43 AM EST - 1 year ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Jan 22, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 10, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 4, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Dec 3, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 26, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Nov 7, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Ensysce Biosciences Receives Notice from Nasdaq

Sep 27, 2024, 4:30 PM EDT - 1 year ago

Ensysce Biosciences Receives Notice from Nasdaq

Ensysce Biosciences Presenting at Upcoming Meetings

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Presenting at Upcoming Meetings

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Aug 27, 2024, 2:30 PM EDT - 1 year ago

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Bhaddar1
Bhaddar1 Feb. 23 at 9:58 PM
$ENSC we looking for next jumb for .50 range and then we off to moon 🌙
0 · Reply
Djdanny
Djdanny Feb. 23 at 9:28 PM
$ENSC Super hammered stock .Potential gg reward.
0 · Reply
Ctr_
Ctr_ Feb. 23 at 9:15 PM
$ENSC has been going sideways .35 & .38 since feb 18. waiting for structure
0 · Reply
Big_Zack22
Big_Zack22 Feb. 23 at 7:44 PM
$ENSC Hold on my budy
0 · Reply
Big_Zack22
Big_Zack22 Feb. 23 at 7:27 PM
$ENSC loading zone
0 · Reply
PTI127
PTI127 Feb. 23 at 2:19 PM
$ENSC gifted here buy and hold 😘
1 · Reply
ttesty
ttesty Feb. 23 at 2:07 PM
$ENSC on the road to $0.
1 · Reply
Bhaddar1
Bhaddar1 Feb. 23 at 12:33 PM
$ENSC loud up 🆙
0 · Reply
Magnatar
Magnatar Feb. 23 at 3:27 AM
$ENSC “Dark Pool Ale” - Bring It $$
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 12:39 AM
$ENSC RSI: 26.64, MACD: -0.1566 Vol: 0.18, MA20: 0.58, MA50: 0.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Sunnybhargava
Sunnybhargava Feb. 23 at 12:02 AM
$ENSC
0 · Reply
BULLISH1975
BULLISH1975 Feb. 22 at 10:39 PM
$ENSC I would love Lynn to request a third party to do a share count!!!! I bet there are millions and millions of fake, synthetic and FTDs here!!!!! such a corrupt system. terrible for honest retail trying to pick a good company when there is a lawless market in place for the big kids!!!! very sad. i wish retail would join forces !!! dyor
1 · Reply
REXOM
REXOM Feb. 22 at 4:21 PM
$MGRX $TRNR $ENSC $AGAE $TOVX
0 · Reply
Buccmarine
Buccmarine Feb. 22 at 2:26 AM
$ENSC he really cares and don’t want us to lose our money….
1 · Reply
Sunnybhargava
Sunnybhargava Feb. 22 at 12:31 AM
$ENSC why you wasting your time here go somewhere else
0 · Reply
Buccmarine
Buccmarine Feb. 21 at 9:55 PM
$ENSC so why waste your time posting for the 1000th time? 🤷‍♂️
0 · Reply
ttesty
ttesty Feb. 21 at 9:26 PM
$ENSC it's funny watching all these newbies who weren't in here a month ago, suddenly come in and try to scam up because they saw a discord scam work for a day or two.
0 · Reply
ttesty
ttesty Feb. 21 at 9:24 PM
For the 1000th time... $ENSC is a SCAM. Can't you see? Target is $0.
1 · Reply
REXOM
REXOM Feb. 21 at 3:04 PM
We BANKED on my FREE DISCORD last week. The link is under my bio. My TOP calls for LAST WEEK ( part -3- ) were : 1- $MGRX 0.51 - 0.63 2- $TRNR 0.48 - 0.69 3- $ENSC 0.42 - 0.70 4- $AGAE 0.37 - 0.58 5- $TOVX 0.23 - 0.33
0 · Reply
Buccmarine
Buccmarine Feb. 21 at 4:17 AM
$ENSC
2 · Reply
Jlh50
Jlh50 Feb. 21 at 2:54 AM
$ENSC What’s the competition look like? Are there other companies working on similar products or does the company have a pretty clear path to commercialization?
1 · Reply
turtlehare
turtlehare Feb. 21 at 2:47 AM
$ENSC hard to believe how this has just plummeted to irrelevance so quickly ! Absolute junk
1 · Reply